Imatinib for systemic mast-cell disease

Lancet

Volumn 362, Issue 9383, 2003, Pages 535-537

  Pardanani, A ^a   Elliott, M ^a   Reeder, T ^a   Li, C Y ^a   Baxter, E J ^b   Cross, N C P ^b   Tefferi, A ^a  

^a MAYO CLINIC   (United States)

^b SALISBURY DISTRICT HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; STEM CELL FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG TARGETING; EOSINOPHILIA; HEMATOLOGY; HEPATOMEGALY; HISTOLOGY; HUMAN; MASTOCYTOMA; MUTATION; PRIORITY JOURNAL; SPLENOMEGALY; TREATMENT OUTCOME; TUMOR REGRESSION;

EID: 0041656424     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14115-3     Document Type: Article

References (5)

1. Furitsu T., Tsujimura T., Tono T., Ikeda H., Kitayama H., Koshimizu U., et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukaemia cell line causing ligand- independent activation of c-kit product. J Clin Invest. 92:1993;1736-1744.
2. Heinrich M.C., Griffith D.J., Druker B.J., Wait C.L., Ott K.A., Zigler A.J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 96:2000;925-932.
3. Ma Y., Zeng S., Metcalfe D.D., et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 99:2002;1741-1744.
4. Yavuz A.S., Lipsky P.E., Yavuz S., Metcalfe D.D., Akin C. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood. 100:2002;661-665.
5. Gleich G.J., Leiferman K.M., Pardanani A., Tefferi A., Butterfield J.H. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 359:2002;1577-1578.